Qlife Holding AB (OSTO:QLIFE) FFO


OSTO:QLIFE Qlife Holding AB OSTO:QLIFE
15 GF Score
Price kr1.93
GF Value kr0.76
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Qlife Holding AB FFO?

FFO (Funds from operations) only applies to REITs.

OSTO:QLIFE
15GF Score
Qlife Holding AB OSTO:QLIFE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued. The current stock price of kr1.93 is trading 153.9% above its estimated GF Value™ of kr0.76. GuruFocus considers Qlife Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:QLIFE:

  • FFO:
  • GF Value™: kr0.76 vs. price of kr1.93 (153.9% above fair value)
  • GF Score™: 15/100 with 9 warning signs

No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Qlife Holding AB Business Description

Other Exchanges 4HG0:Germany
Address Nellikevagen 22, Goteborg, SWE, SE-412 63
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
15GF Score

Get the complete analysis for OSTO:QLIFE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.93
Price
kr0.76
GF Value